Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Pharm Dev Technol ; 13(3): 221-31, 2008.
Article in English | MEDLINE | ID: mdl-18484491

ABSTRACT

We developed and tested ocular inserts containing epidermal growth factor (EGF) for a causal treatment of keratoconjunctivitis sicca (KCS). The inserts, consisting of different alginates with hydroxyethylcellulose (HEC) as a lubricant and release modifier, released EGF over time periods ranging from a few hours up to several days. The stability of EGF was high, having a protein half-life of approximately 548 days. A clinical pilot study suggests an amelioration of both the main symptoms and the objective criteria: tear film break-up (BUT) time and lissamine green score. Our results show that EGF treatment of KCS is highly promising.


Subject(s)
Alginates/chemistry , Epidermal Growth Factor/administration & dosage , Epidermal Growth Factor/therapeutic use , Keratoconjunctivitis Sicca/drug therapy , Adolescent , Adult , Alginates/administration & dosage , Chemistry, Pharmaceutical , Chromatography, High Pressure Liquid , Cross-Linking Reagents , Delayed-Action Preparations , Drug Implants , Epidermal Growth Factor/analysis , Excipients , Female , Glucuronic Acid/administration & dosage , Glucuronic Acid/chemistry , Hexuronic Acids/administration & dosage , Hexuronic Acids/chemistry , Humans , Male , Spectrometry, Fluorescence
SELECTION OF CITATIONS
SEARCH DETAIL
...